UA129890C2 - ТІЄНО[3,2-b]ПІРИДИН-7-АМІНОВІ СПОЛУКИ ДЛЯ ЛІКУВАННЯ СІМЕЙНОЇ ДИЗАВТОНОМІЇ - Google Patents

ТІЄНО[3,2-b]ПІРИДИН-7-АМІНОВІ СПОЛУКИ ДЛЯ ЛІКУВАННЯ СІМЕЙНОЇ ДИЗАВТОНОМІЇ

Info

Publication number
UA129890C2
UA129890C2 UAA202105103A UAA202105103A UA129890C2 UA 129890 C2 UA129890 C2 UA 129890C2 UA A202105103 A UAA202105103 A UA A202105103A UA A202105103 A UAA202105103 A UA A202105103A UA 129890 C2 UA129890 C2 UA 129890C2
Authority
UA
Ukraine
Prior art keywords
chloro
methyl
amino
pyridin
amine
Prior art date
Application number
UAA202105103A
Other languages
English (en)
Ukrainian (uk)
Inventor
Наньцзин ЧЖАН
Майкл А. Арнольд
Амал Дакка
Ґарі Мітчелл Керп
Гари Митчелл Керп
Том Туан Луонґ
Том Туан Луонг
Джейна Наресімхен
Джэйна Наресимхен
Ніколай А. Наришкін
Николай А. Наришкин
Цзяши ВАН
Сяоянь Чжан
Original Assignee
ПіТіСі ТЕРАПЬЮТИКС, ІНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ПіТіСі ТЕРАПЬЮТИКС, ІНК. filed Critical ПіТіСі ТЕРАПЬЮТИКС, ІНК.
Publication of UA129890C2 publication Critical patent/UA129890C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UAA202105103A 2019-02-13 2020-02-10 ТІЄНО[3,2-b]ПІРИДИН-7-АМІНОВІ СПОЛУКИ ДЛЯ ЛІКУВАННЯ СІМЕЙНОЇ ДИЗАВТОНОМІЇ UA129890C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962805283P 2019-02-13 2019-02-13
PCT/US2020/017430 WO2020167628A1 (en) 2019-02-13 2020-02-10 Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia

Publications (1)

Publication Number Publication Date
UA129890C2 true UA129890C2 (uk) 2025-09-03

Family

ID=69960696

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA202105103A UA129890C2 (uk) 2019-02-13 2020-02-10 ТІЄНО[3,2-b]ПІРИДИН-7-АМІНОВІ СПОЛУКИ ДЛЯ ЛІКУВАННЯ СІМЕЙНОЇ ДИЗАВТОНОМІЇ

Country Status (17)

Country Link
US (1) US12384797B2 (https=)
EP (1) EP3924049A1 (https=)
JP (1) JP7587511B2 (https=)
KR (1) KR102907028B1 (https=)
CN (1) CN113795304A (https=)
AU (1) AU2020222881C1 (https=)
BR (1) BR112021015853A2 (https=)
CA (1) CA3129067A1 (https=)
CL (1) CL2021002137A1 (https=)
CO (1) CO2021010598A2 (https=)
EA (1) EA202192170A1 (https=)
IL (1) IL285399B2 (https=)
MX (1) MX2021009667A (https=)
PE (1) PE20220139A1 (https=)
SG (1) SG11202108519TA (https=)
UA (1) UA129890C2 (https=)
WO (1) WO2020167628A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
SG11202108519TA (en) 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
CN115209955A (zh) * 2019-12-12 2022-10-18 Ptc医疗公司 治疗家族性自主神经功能障碍的化合物
BR112022023025A2 (pt) 2020-05-13 2023-03-28 Chdi Foundation Inc Moduladores de htt para tratar doença de huntington
EP4277626A4 (en) * 2021-01-14 2024-12-11 Georgetown University USP13 INHIBITORS AND METHODS OF USE THEREOF
CN112920053B (zh) * 2021-02-01 2022-07-01 暨明医药科技（苏州）有限公司 一种手性α-甲基芳乙胺的制备方法
EP4288059A4 (en) * 2021-02-05 2025-01-08 PTC Therapeutics, Inc. Compounds for treating spinocerebellar ataxia type 3
US20240041886A1 (en) * 2021-02-05 2024-02-08 Ptc Therapeutics, Inc. Methods for treating spinocerebellar ataxia type 3
US20240051968A1 (en) * 2021-02-05 2024-02-15 Ptc Therapeutics, Inc. Methods for treating spinocerebellar ataxia type 3
TW202313623A (zh) 2021-06-03 2023-04-01 大陸商江蘇恆瑞醫藥股份有限公司 具有整合酶抑制活性的吡啶酮化合物及其藥用用途
EP4398987A4 (en) * 2021-09-07 2025-07-09 Ptc Therapeutics Inc METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES
US20250127789A1 (en) * 2021-11-04 2025-04-24 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
US12281116B2 (en) 2021-11-17 2025-04-22 Chdi Foundation, Inc. HTT modulators for treating Huntington's disease
WO2023212237A1 (en) 2022-04-27 2023-11-02 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
US20260001889A1 (en) 2022-05-12 2026-01-01 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
MA71255A (fr) * 2022-06-22 2025-04-30 Ptc Therapeutics, Inc. Composés pour le traitement de l'ataxie spinocérébelleuse de type 3
WO2024036143A2 (en) * 2022-08-09 2024-02-15 Ptc Therapeutics, Inc. Methods for modulating rna splicing

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
JP3126541B2 (ja) 1993-03-26 2001-01-22 千寿製薬株式会社 ベンゾチアゾール誘導体、その製法及びその用途
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
NZ335823A (en) 1997-04-22 2001-06-29 Neurocrine Biosciences Inc Thiophenopyridines, preparation as CRF receptor antagonists
EP1028964A1 (en) 1997-11-11 2000-08-23 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
WO2004065392A1 (en) 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
WO2005007083A2 (en) 2003-06-18 2005-01-27 Smithkline Beecham Corporation Chemical compounds
CA2540681C (en) 2003-10-03 2014-08-12 The General Hospital Corporation Methods for altering mrna splicing and treating familial dysautonomia and other mechanistically related disorders
JP2009007341A (ja) 2007-06-01 2009-01-15 Mitsubishi Tanabe Pharma Corp 医薬組成物
EP2014663A1 (de) 2007-07-12 2009-01-14 Bayer Schering Pharma AG Thienopyrimidylamine als Modulatoren des EP2-Rezeptors
WO2009085226A2 (en) 2007-12-21 2009-07-09 Sirtris Pharmaceuticals, Inc. Inhibitors of cdc2-like kinases (clks) and methods of use thereof
BRPI0912245A2 (pt) 2008-03-05 2019-09-24 Takeda Pharmaceuticals Co composto, prodroga, medicamento, métodos de suprimir produção de açúcar em um mamífero e para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso do composto
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
WO2012012656A2 (en) 2010-07-21 2012-01-26 University Of South Florida Materials and methods for treating neurodegenerative diseases
EP2611812A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
DE102011111400A1 (de) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
EP2867236B1 (en) 2012-06-29 2017-06-14 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
WO2014124458A1 (en) 2013-02-11 2014-08-14 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases
CN105339371A (zh) 2013-03-07 2016-02-17 葛兰素史密斯克莱有限责任公司 作为沉默调节蛋白调节剂的噻吩并[3,2-d]嘧啶-6-甲酰胺和类似物
CN110218727A (zh) 2013-03-14 2019-09-10 萨勒普塔医疗公司 用于治疗肌营养不良的外显子跳跃组合物
CN103242341B (zh) 2013-04-19 2015-12-09 中国科学院广州生物医药与健康研究院 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用
US9879014B2 (en) * 2013-07-12 2018-01-30 Kyoto University Method for screening substance capable of inhibiting abnormal splicing causative of onset or progress of disease
RU2692634C2 (ru) 2013-10-07 2019-06-25 Академиш Зикенхойс Лейден Х.О.Д.Н. Люмк Направляемое антисмысловым олигонуклеотидом удаление сайтов протеолитического расщепления, мутации hchwa-d и увеличенного числа тринуклеотидных повторов
KR102390370B1 (ko) 2014-02-12 2022-04-26 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
MA39987A (fr) 2014-04-30 2017-03-08 Incyte Corp Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées
CA2973949C (en) 2015-01-16 2023-07-11 The General Hospital Corporation Compounds for improving mrna splicing
ES2865330T3 (es) 2015-04-29 2021-10-15 Janssen Pharmaceutica Nv Azabenzimidazoles y su uso como moduladores del receptor AMPA
KR102222186B1 (ko) 2015-08-13 2021-03-03 머크 샤프 앤드 돔 코포레이션 Sting 효능제로서 시클릭 디-뉴클레오티드 화합물
EP4285912A3 (en) 2015-09-25 2024-07-10 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating ataxin 3 expression
IL294124B2 (en) 2015-12-10 2024-02-01 Ptc Therapeutics Inc Methods for treating huntington's disease
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
EP3494229B1 (en) 2016-08-03 2023-10-25 Meiragtx UK II Limited High throughput cell-based screening for aptamers
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
WO2018151326A1 (ja) 2017-02-20 2018-08-23 国立大学法人京都大学 スプライシング異常に起因する遺伝性疾病のための医薬組成物及び治療方法
US10538571B2 (en) 2017-11-27 2020-01-21 Coda Biotherapeutics, Inc. Compositions and methods for neurological diseases
WO2020123395A1 (en) 2018-12-10 2020-06-18 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
CN109819066A (zh) 2019-01-31 2019-05-28 平安科技（深圳）有限公司 一种基于地理位置的智能解析域名方法及装置
SG11202108519TA (en) 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
MA54953A (fr) 2019-02-13 2021-12-22 Denali Therapeutics Inc Composés, compositions et procédés
EP3929185A4 (en) 2019-02-19 2023-02-15 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NITROGEN CONDENSED CYCLIC COMPOUND, METHOD OF PRODUCTION THEREOF AND USE THEREOF
CN113950529A (zh) 2019-06-06 2022-01-18 豪夫迈·罗氏有限公司 靶向atxn3的反义寡核苷酸
US11798161B2 (en) 2019-11-26 2023-10-24 Koh Young Technology Inc. Method and apparatus for determining mid-sagittal plane in magnetic resonance images
CN115209955A (zh) 2019-12-12 2022-10-18 Ptc医疗公司 治疗家族性自主神经功能障碍的化合物
US20230117831A1 (en) 2020-01-08 2023-04-20 The Broad Institute, Inc. Multi-functional chimeric molecules
US20240051968A1 (en) 2021-02-05 2024-02-15 Ptc Therapeutics, Inc. Methods for treating spinocerebellar ataxia type 3
EP4288059A4 (en) 2021-02-05 2025-01-08 PTC Therapeutics, Inc. Compounds for treating spinocerebellar ataxia type 3
EP4288441A4 (en) 2021-02-05 2024-12-11 PTC Therapeutics, Inc. Methods for treating spinocerebellar ataxia type 3
JP2024513566A (ja) 2021-04-09 2024-03-26 ザ・ブロード・インスティテュート・インコーポレイテッド 標的基質の選択的修飾のための二官能性分子
EP4398987A4 (en) 2021-09-07 2025-07-09 Ptc Therapeutics Inc METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES
CN118251225A (zh) 2021-09-07 2024-06-25 Ptc医疗公司 治疗神经退行性疾病的方法
MX2024002887A (es) 2021-09-07 2024-05-28 Ptc Therapeutics Inc Metodos para tratar enfermedades neurodegenerativas.
US20250127789A1 (en) 2021-11-04 2025-04-24 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
MA71255A (fr) 2022-06-22 2025-04-30 Ptc Therapeutics, Inc. Composés pour le traitement de l'ataxie spinocérébelleuse de type 3

Also Published As

Publication number Publication date
BR112021015853A2 (pt) 2021-10-05
PE20220139A1 (es) 2022-01-27
IL285399B2 (en) 2025-06-01
IL285399B1 (en) 2025-02-01
CL2021002137A1 (es) 2022-02-25
AU2020222881B2 (en) 2025-07-10
WO2020167628A1 (en) 2020-08-20
KR20210137040A (ko) 2021-11-17
JP7587511B2 (ja) 2024-11-20
US12384797B2 (en) 2025-08-12
AU2020222881C1 (en) 2026-01-22
EP3924049A1 (en) 2021-12-22
KR102907028B1 (ko) 2026-01-05
US20220135586A1 (en) 2022-05-05
CO2021010598A2 (es) 2021-08-30
AU2020222881A1 (en) 2021-09-09
CA3129067A1 (en) 2020-08-20
EA202192170A1 (ru) 2021-11-15
IL285399A (en) 2021-09-30
SG11202108519TA (en) 2021-09-29
JP2022520822A (ja) 2022-04-01
MX2021009667A (es) 2021-12-10
CN113795304A (zh) 2021-12-14

Similar Documents

Publication Publication Date Title
UA129890C2 (uk) ТІЄНО[3,2-b]ПІРИДИН-7-АМІНОВІ СПОЛУКИ ДЛЯ ЛІКУВАННЯ СІМЕЙНОЇ ДИЗАВТОНОМІЇ
CZ20013000A3 (cs) Nové sulfonamidové sloučeniny a jejich pouľití
AU2020323429A1 (en) Urea compound for antagonizing LPA1 receptor
CA3023465A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
UA110688C2 (uk) Біциклічні піридинони
MX2010013351A (es) Derivados de indano como reguladores del receptor de ampa.
EP4335848A2 (en) Dual magl and faah inhibitors
WO2021118929A1 (en) Compounds for treating familial dysautonomia
DE69810800T2 (de) Azetidinonderivate zur behandlung von hcmv entzündungen
DE69907845T2 (de) Sulfonamid-Derivate
US10919911B2 (en) Tricyclic ASK1 inhibitors
WO2015158426A1 (en) Aryl substituted heterocyclyl sulfones
BR112020014833A2 (pt) Compostos para o tratamento de infecções parasitárias
WO2023049369A2 (en) Pyridinyl derivatives as sodium channel activators
CA3202085A1 (en) Progranulin modulators and methods of using the same
CA3160368A1 (en) Substituted imidazolecarboxamide as bruton's tyrosine kinase inhibitors
EP4514806B1 (en) Compositions useful for modulating splicing
BR122024013729A2 (pt) Compostos de tieno[3,2-b]piridin-7-amina, seus usos no tratamento de disautonomia familiar e composição farmacêutica compreendendo os mesmos
KR101771698B1 (ko) 5-아미노-4-하이드록시펜토일 아미드
HK40065747A (zh) 用於治疗家族性自主神经功能障碍的噻吩并[3，2-b]吡啶-7-胺化合物
HK1233249A1 (en) Bace1 inhibitors